IQVIA's Healthcare Data & Analytics Product Portfolio

IQVIA provides a suite of data-management platforms to integrate, standardize, and govern healthcare information across organizations. Key products include:

• Data-as-a-Service (DaaS): A cloud-based solution that centralizes healthcare data from diverse sources into a single platform (^[3]) (^[4]). DaaS enables companies to source, host, standardize and access large volumes of patient, claims and commercial data in a unified format, accelerating insights and analytics.
• Integrated Data Platform (IDP): A modern data warehouse and management system optimized for life sciences. IDP rapidly connects multiple data sources (sales, patient, claims, EMR, etc.) so that analytics-ready insights can be generated in weeks rather than months (^[5]) (^[6]).
• Master Data Management (MDM): A centralized system for harmonizing enterprise master data (e.g. products, providers, facilities) to ensure a single source of truth. IQVIA MDM consolidates and updates key reference data across commercial and R&D domains for regulatory compliance and omnichannel engagements (^[7]).
• Data Governance and Stewardship: Governance tools and processes that enforce data quality, consistency and compliance. This solution provides a framework for maintaining trusted datasets and tracking data lineage across IQVIA’s information systems (^[8]).
• Data Bridging: A highly configurable tool for linking disparate data sources. Data Bridging matches, merges and enriches datasets (e.g. patient registries, survey data) against reference files to uncover common IDs and fill data gaps (^[9]).

These platforms are built on IQVIA’s Human Data Science Cloud and leverage the IQVIA Global Data Model (GDM): a comprehensive healthcare data standard referenced in the DaaS architecture (^[10]). Combined, these products help organizations accelerate data integration, improve data quality, and enable faster analytics across the enterprise.

IQVIA offers a range of commercial software for sales, marketing and medical affairs teams. The cornerstone has been the Orchestrated Customer Engagement (OCE) platform (^[11]). OCE is a cloud-based CRM and engagement platform that supports personalized, multichannel interactions with healthcare professionals (HCPs) across sales, marketing, and medical-affairs workflows. IQVIA has described its technology suite as using best-in-class platforms including Salesforce, rather than as being built solely on Salesforce (^[12]). OCE modules include OCE Sales, OCE Marketing, OCE Digital, OCE Connect, OCE Personal, OCE Remote Engagement, OCE Optimizer, and OCE+ for enhanced features. The platform was deployed globally by major pharma companies including Roche across 14,000 users in 100+ countries.

Important transition: In April 2024, IQVIA said it would license OCE CRM-related software to Salesforce and collaborate on Salesforce Life Sciences Cloud for customer engagement. IQVIA also said it would continue marketing OCE CRM and support its nearly 400 global OCE customers in 130+ countries through 2029 as the companies coordinate a transition (^[13]).

Additional customer-engagement products include:

• IQVIA ePromo: a cloud-based Content Management solution for life sciences. Launched in 2018, ePromo streamlines the creation, approval, dissemination and withdrawal of regulated promotional and medical materials (^[14]). It provides workflow management, role-based dashboards and compliance controls to speed time-to-market for ads and detail aids.
• Organization Manager: IQVIA describes this as a solution for accelerating field alignment, helping sales and marketing teams use CRM and reference data to identify and act on commercial opportunities (^[15]).
• Incentive 360: IQVIA’s incentive-compensation platform, designed to help commercial organizations design, measure, and reward field-force performance using advanced insights and motivational tools (^[16]).
• Promo Suite and Omnichannel Navigator: solutions for multi-channel promotional planning. Promo Suite uses advanced analytics to optimize channel spending, while Omnichannel Navigator coordinates marketing touchpoints for personalized campaign execution (^[17]).
• OCE Optimizer: an add-on to OCE that permits detailed planning and real-time adjustment of HCP call plans and sales resources.

These commercial solutions are often integrated. For example, the Roche implementation in 2018 combined OCE (Sales and Marketing), MDM, ePromo, and Organization Manager into a unified suite to transform commercial operations (^[11]).

IQVIA offers a broad analytics platform portfolio for business intelligence, market analytics, and performance management. A flagship offering is IQVIA Orchestrated Analytics (OA) (^[18]). Orchestrated Analytics is a unified BI platform built on IQVIA’s data and AI infrastructure. It allows brand and operations teams to harness decision intelligence across the commercial lifecycle (^[18]).

Notable analytics products include:

• IQVIA Personalization Hub: A role-based BI and analytics platform. It delivers tailored dashboards and recommendations through an AI-driven interface, improving user adoption and insights delivery (^[19]).
• IQVIA Next Best Action (NBA): A prescriptive analytics engine that surfaces “next best” HCP recommendations. NBA embeds machine-learning intelligence into workflows so that sales and marketing teams can target the right customers with optimal actions (^[20]).
• Gross-to-Net and Supply Integrity: Solutions for pricing and manufacturing. Gross-to-Net automates calculation of pricing waterfalls and deductions, while the Supply Integrity Management System (SIS) supports product supply planning and contract compliance (^[17]).

Together these analytics tools help life sciences organizations track performance in real time and derive actionable insights. For example, brands use these platforms to optimize marketing spend, forecast sales, and continuously adjust strategy based on data.

IQVIA maintains one of the world’s largest real-world data assets and provides tools to access it. The IQVIA E360 Real World Data Platform is a self-service analytics environment for epidemiology, outcomes research, and clinical development (^[21]). E360 brings together over a billion de-identified patient records (claims, electronic medical records, patient registries, etc.) in a single portal. It enables researchers to rapidly query global RWD in weeks instead of months (^[21]) (^[22]). Concrete use cases include informing clinical trial design, safety monitoring, and health economics studies.

IQVIA also offers an extensive catalog of curated RWD assets and an evidence-generation framework. (For example, the IQVIA Health Data Catalog helps study teams identify appropriate datasets for specific research questions.) These real-world evidence solutions leverage the same Integrated Data Platform and HDS Cloud infrastructure to ensure data are standardized and compliant.

The Observational Medical Outcomes Partnership (OMOP) Common Data Model is relevant to specified IQVIA real-world-data offerings. IQVIA states that direct data delivery through Analytics Research Accelerator (ARA) is available in OMOP format and describes OMOP-enabled use of IQVIA data assets and federated analysis with network partners (^[23]). IQVIA’s June 2025 blog also describes the general interoperability and analysis benefits it associates with OMOP, but this does not establish that IQVIA’s entire real-world-data estate is OMOP-mapped (^[24]). The OMOP CDM is an open community data standard designed to standardize the structure and content of observational data and support efficient, standardized analyses across disparate databases (^[25]).

Sitting above the individual data and analytics products is IQVIA Connected Intelligence, the company's umbrella framing for how its data assets, analytics engines, AI, and domain expertise interoperate rather than function as isolated tools (^[26]). In practice, Connected Intelligence is less a single purchasable product than a positioning layer: IQVIA describes it as connecting evidence networks in R&D, AI-enabled clinical trial financial management, real-world evidence study design, unstructured-text analytics, and commercial engagement into one continuous data fabric (^[27]). For buyers, Connected Intelligence is best understood as IQVIA’s positioning for how its offerings and expertise can work together; pricing, packaging, interoperability, and transition terms should be evaluated for the specific products under consideration.

IQVIA does not operate unchallenged. Several specialized vendors compete for slices of the same commercial-analytics and real-world-evidence budget, generally by emphasizing depth in one data modality rather than IQVIA's breadth across prescriber, claims, EHR, and clinical trial data simultaneously.

• Komodo Health offers the "Healthcare Map," which the company describes as a longitudinal, de-identified healthcare dataset supporting patient-journey analytics (^[28]). Its suitability relative to IQVIA depends on the study question, required data modalities, geographic coverage, and analytics workflow.
• Symphony Health, long a commercial-data rival to IQVIA, has changed hands twice in recent years. PRA Health Sciences acquired it in 2017, and PRA later became part of ICON plc (^[29]). In May 2026, HealthVerity completed its acquisition of Symphony Health from ICON, combining HealthVerity's clinical data capabilities with Symphony's commercial-data business (^[30]). This ownership history illustrates consolidation around Symphony Health, but does not by itself establish a conclusion about stability across the entire commercial real-world-data segment.
• Optum (UnitedHealth Group's data and analytics arm) offers linked claims and EHR assets for life sciences customers, including its Market Clarity product, which combines medical and pharmacy claims with electronic health record data across a large, de-identified patient population and more than a billion prescription records (^[31]). The relative suitability of Optum and IQVIA data depends on the study question, required data modalities, geographic coverage, and analytics workflow.
• Definitive Healthcare competes on a different axis entirely, health-system, hospital, and clinician reference and affiliation data used for market intelligence, sales targeting, and provider network analysis, rather than patient-level longitudinal RWD (^[32]). Because the datasets answer different questions (who the providers are versus what patients experienced), Definitive Healthcare data may complement an IQVIA or Komodo subscription rather than replace it.

Sponsors evaluating this landscape typically weigh three variables: depth of a given data type (claims, EHR, prescriber, hospital affiliation), geographic coverage for the specific data assets and study population, and whether the vendor also supplies the analytics and workflow layer or only raw data access. Buyers should verify current geographic coverage directly with each vendor rather than assume it creates a consistent competitive advantage.

Real-world data platforms of the kind IQVIA and its competitors sell are shaped heavily by regulatory expectations for how RWD may be used as RWE, and by privacy law governing the underlying patient information.

On the regulatory-decision-making side, the U.S. FDA published its Framework for FDA's Real-World Evidence Program in December 2018 and has since finalized related guidance on considerations for using real-world data and real-world evidence to support regulatory decisions for drugs and biologics, covering data reliability and relevance, transparency, and early agency engagement expectations (^[33]) (^[34]). In the European Union, the EMA finalized a companion Data Quality Framework for real-world data, adopted by the CHMP and developed jointly with the Heads of Medicines Agencies and the TEHDAS initiative, which assesses RWD fitness-for-use against a specific research question rather than fixed numeric thresholds (^[35]). These frameworks matter directly to IQVIA's commercial pitch: tools such as Analytics Research Accelerator (ARA) and OMOP-based evidence networks may be used to support RWE work, but suitability for a regulatory decision depends on the specific data, study design, and regulatory context.

For U.S. protected health information held by HIPAA covered entities or their business associates, the HIPAA Privacy Rule provides two de-identification methods: Safe Harbor, which removes eighteen specified identifier types and requires no actual knowledge that the remaining information could identify an individual, and Expert Determination, in which a qualified expert determines that re-identification risk is very small (^[36]). HIPAA does not by itself govern every IQVIA dataset or every jurisdiction.

Enterprise buyers of IQVIA's data and analytics stack generally fall into three overlapping use cases. Commercial analytics teams use Orchestrated Analytics, Personalization Hub, and Next Best Action to plan field-force deployment, monitor brand performance, and optimize marketing spend in near real time. Regulatory and market-access teams may use Analytics Research Accelerator (ARA) and related real-world-data resources to support evidence-generation work for regulatory submissions, post-approval commitments, and payer value dossiers. Whether resulting RWE is suitable for a particular regulatory decision depends on the specific question and the relevance, reliability, and fitness for use of the data and study design, as assessed by the relevant authority. Health-economics and outcomes research (HEOR) groups sit between the two, using RWD to build the comparative-effectiveness and budget-impact arguments that market-access teams then present to payers.

Contracting and pricing for this category are scope-specific. IQVIA does not publish a general list price for the data and analytics products described here, so prospective buyers should request a quote based on the required data, users, services, and implementation scope. When considering multiple IQVIA products, buyers should evaluate interoperability, transition terms, pricing, and the implications of adopting a broader suite during procurement.

In January 2025, IQVIA announced a strategic collaboration with NVIDIA to build domain-expert agentic AI solutions for healthcare and life sciences (^[2]). By June 2025, IQVIA launched multiple AI orchestrator agents covering trial start-up, target identification, clinical data review, literature review, market assessment, and HCP engagement (^[37]). These agents leverage NVIDIA NIM Agent Blueprints, NeMo Customizer for fine-tuning, and NeMo Guardrails for safe deployment.

Additionally, IQVIA announced the Clinical Trial Financial Suite (CTFS) in September 2025, an AI-enabled platform for clinical-trial financial management; at that time, it said the first module was planned for general commercial availability in Q1 2026. In March 2026, IQVIA announced general availability of CTFS, including CTFS Site Payments and new AI-driven capabilities (^[38]). The company had described up to a 50% reduction in payment-processing time as an expected customer outcome, rather than an established realized result (^[39]).

Beyond the above categories, IQVIA has additional specialized software offerings:

• Quality and Compliance Software: Systems for GxP compliance, not covered here in detail. (IQVIA's legacy includes Trial Master File and pharmacovigilance apps, although many have been incorporated into broader offerings.)
• Investigator and Site Solutions: Tools for clinical trial site management and patient engagement (e.g. eConsent, mobile health). These include IQVIA's clinical trial management (CTMS) solutions and patient recruitment platforms.
• Data Licensing and Syndicated Research: IQVIA licenses commercial data products, such as sales and disease-prevalence data, as subscription services that can support analytics and real-world-data workflows. MarketScan is not an IQVIA asset; it is a Merative real-world-data portfolio.
• Identity Resolution and Audience Activation: Throtle, an IQVIA-owned company, provides healthcare identity-resolution and audience-activation capabilities for connecting healthcare marketing data across channels (^[40]).

Summary: IQVIA's product portfolio spans data management, analytics, AI-powered automation, and domain-specific solutions. Key offerings include cloud analytics platforms (Orchestrated Analytics, Personalization Hub, Next Best Action), engagement systems (OCE CRM transitioning to Salesforce Life Sciences Cloud, ePromo, Incentive 360), data platforms (DaaS, Integrated Data Platform, and Analytics Research Accelerator), master data governance tools, and a growing suite of AI agents built with NVIDIA (^[41]) (^[42]). These products are often integrated into comprehensive suites; for example, pharmaceutical companies deploy analytics and engagement platforms together to optimize launch and field operations. With $16.3 billion in 2025 revenue and 2026 revenue guidance of $17.15 billion to $17.35 billion, IQVIA continues investing in AI and data capabilities (^[43]). The unifying theme remains "human data science": leveraging IQVIA's healthcare datasets and AI to support faster decision-making and research across life sciences (^[38]).